A recent study published in the Journal of Alzheimer’s Disease has provided new insights into the effects of treatment on patients with Alzheimer’s disease (AD). The research, led by Dr. et al., explored the relationship between cognitive decline and functional independence in AD patients treated with lecanemab and donanemab.
The study, which included 282 participants, found that these treatments can slow cognitive decline and extend patients’ independence in daily activities. Specifically, it was observed that approximately 50% of participants were dependent on assistance with everyday tasks, such as preparing meals and managing medications.
However, the study also revealed that lecanemab and donanemab can increase the risk of amyloid-related neuroimaging abnormalities (ARIA), which may be a concern for physicians initiating these therapies. As a result, the treatments must demonstrate significant clinical benefits to outweigh the potential risks and costs.
The study’s findings suggest that patients with mild AD dementia (CDR score 1) had significantly lower rates of independence in instrumental activities of daily living (IADLs) compared to those with very mild AD dementia (CDR score 0.5). Conversely, participants with CDR-SB scores below 4.5 were more likely to be independent in IADLs.
The researchers found that the average annual increase in CDR-SB was 1.30, but this rate decreased when patients received lecanemab or donanemab treatments. The study also discovered that these treatments can add several months of independence in IADLs and daily living activities.
While the study’s findings are promising, it is essential to note that the clinical significance of these treatments remains a topic of debate among healthcare professionals. As a result, caregivers and family members must carefully weigh the potential benefits against the risks and costs associated with these therapies.
Source: https://www.news-medical.net/news/20250217/Lecanemab-and-donanemab-slow-Alzheimere28099s-decline-but-is-the-benefit-worth-the-cost.aspx